A Minority Shareholder’s €1.4 Billion Claim Is Overshadowing CSG’s Record Orders and Index Promotion

CSG shares collapse 60% from January high as €1.4B legal dispute with minority shareholder overshadows record €17B order book and strong Q1 earnings.

A new joint venture to produce electronic fuses for NATO-standard large-calibre ammunition, a slot in Amsterdam’s AMX mid-cap index, and a €17 billion order backlog that keeps growing. On paper, the Czechoslovak Group (CSG) looks unstoppable. Yet its shares have collapsed roughly 60% from the January high, trading at €14.36 as the market fixates on a legal dispute that no amount of operational momentum seems able to dispel.

The latest operational milestone came this week when CSG partnered with South Africa’s Reunert to create Fuchs Electronics Europe. The new entity, in which Reunert holds 51% and CSG 49%, will manufacture electronic fuses for large-calibre munitions at a facility in Dubnica nad Váhom, Slovakia. Two European NATO members have already placed orders in the high double-digit millions of euros, with deliveries scheduled to begin before year-end. The plant, which leverages existing infrastructure, is expected to reach profitability within three years.

That deal sits atop an already formidable first-quarter performance. Revenue came in at €1.544 billion, while net profit surged 83% to €299 million. Operating EBIT rose 8.7% to €372 million, keeping the margin within the targeted 24–25% range. The order book expanded 15.1% to €17 billion, with a further €27 billion in the pipeline under active negotiation. CSG also confirmed its full-year revenue guidance of €7.4 billion to €7.6 billion.

The index upgrade by Euronext to the AMX — reserved for Amsterdam’s 25 most liquid mid-cap stocks — should in theory unlock passive fund flows from ETFs and structured products. So far the market has shrugged. The stock continues to trade at roughly double-digit forward P/E of 16, a deep discount to the European defence sector average of 23.

The governance overhang

The root of the paralysis is a bitter falling-out between CSG and minority shareholder Petr Kratochvíl. He holds about 10% of CSG Land Systems CZ and roughly 9% of the MSM Group, and is demanding €1.4 billion for his stakes. CSG has offered less than a tenth of that figure. The gap — equivalent to roughly 31 billion Czech koruna — has frozen negotiations and dragged in courts in both the Czech Republic and Slovakia. Kratochvíl was removed as chairman in March over a conflict-of-interest allegation, and has since contested both the valuation of his holdings and certain internal share transfers.

For investors, the uncertainty has become the single biggest impediment to a re-rating, despite unanimous enthusiasm from analysts. All ten brokers covering CSG rate the stock a buy, with a median price target of €32.05 — more than double the current level. Berenberg trimmed its estimates after mixed segment results but kept its buy recommendation intact.

Pipeline and technical signals

CSG has been actively tightening its grip on the munitions supply chain. In early June it disclosed that its subsidiary STALUNA TRADE holds just under 10% of the voting rights in Alzchem Group, a German producer of nitroguanidine used in propellants, plus financial instruments covering another roughly 10%. Separately, a licensing partnership with Ukrainian Armor has begun rolling out NATO-standard artillery shells in Ukraine — initially 100,000 rounds of 155mm and 50,000 rounds of 105mm per year, with plans to lift total heavy-calibre output to 850,000 annually by the end of 2026, up from 550,000 in 2025.

Technically, the stock is deeply oversold. The relative strength index stands at 29.3, and the price is more than 24% below its 50-day moving average of €18.96. But such signals have proven insufficient to spark buying interest as long as the legal cloud persists.

The next scheduled event that could shift sentiment is the half-year report on 7 August, with the quiet period beginning on 8 July. Court rulings from Prague or Bratislava could also break the deadlock — in either direction. Until then, CSG’s market value remains hostage to a courtroom drama that its record-breaking order book alone cannot resolve.